The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | The clinical impact of amivantamab and chemotherapy in EGFRm NSCLC
Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, explores the MARIPOSA-2 trial (NCT04487080), which demonstrated a survival advantage with the combination of amivantamab and chemotherapy in patients with EGFR-mutant, advanced non-small cell lung cancer (NSCLC). While the overall survival benefit has not yet reached statistical significance, a significant progression-free survival benefit supports the regimen’s potential. The combination is now approved by the EMA, with FDA approval anticipated. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
